NTK1 Stock Chart & Stats
€0.54
>-€0.01(-0.91%)
At close: 4:00 PM EDT
€0.54
>-€0.01(-0.91%)
Day’s Range― - ―
52-Week Range€0.41 - €0.63
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€17.47M
Enterprise Value€16.47
Total Cash (Recent Filing)€511.00K
Total Debt (Recent Filing)€2.60M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding27,967,531
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio5.74
Price to Book (P/B)1.04
Price to Sales (P/S)5.52
P/FCF Ratio-12.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€40.06K
Bulls Say, Bears Say
Bulls Say
Specialized Investment ModelA focused life-sciences investment model is a durable competitive asset: deep domain expertise and active portfolio support increase the probability that early-stage companies reach commercial milestones and exits. Over 2–6 months this specialization sustains deal flow, value creation and differentiated sourcing.
Improving Revenue TrajectoryConsistent acceleration in revenue indicates the portfolio and operating activities are starting to generate more recurring value. Improving top-line growth combined with historically strong gross margins suggests potential operating leverage as revenues scale, supporting sustained improvement in fundamentals.
Relatively Conservative Leverage HistoricallyHistorically low leverage and a meaningful equity base provide financial flexibility to fund portfolio companies and absorb valuation swings. This structural balance-sheet strength reduces immediate solvency risk and gives the company runway to pursue exits or selective follow-on investments over the medium term.
Bears Say
Persistent Operating LossesSustained negative EBIT/EBITDA indicates the cost base materially exceeds operating revenue. Without structural cost reduction or meaningful scale, persistent operating deficits erode equity and constrain reinvestment capacity, making long-term profitability dependent on exits or transformative margin improvement.
Negative Cash GenerationChronic negative operating and free cash flow create a structural funding need: the business cannot self-sustain operations and must access external capital to cover cash burn. This ongoing dependency elevates execution risk and constrains strategic optionality absent durable cash-flow turnaround.
Dependence On External CapitalA business model reliant on capital raises and realization events ties value creation to capital-market access and exit timing. Over months this reliance can cause dilution, timing risk, and operational constraints if markets tighten or exits slow, weakening the durability of funding for growth and follow-on investments.
NetScientific News
NTK1 FAQ
What was NetScientific PLC’s price range in the past 12 months?
NetScientific PLC lowest stock price was €0.41 and its highest was €0.63 in the past 12 months.
What is NetScientific PLC’s market cap?
NetScientific PLC’s market cap is €17.47M.
When is NetScientific PLC’s upcoming earnings report date?
NetScientific PLC’s upcoming earnings report date is Sep 24, 2026 which is in 45 days.
How were NetScientific PLC’s earnings last quarter?
Currently, no data Available
Is NetScientific PLC overvalued?
According to Wall Street analysts NetScientific PLC’s price is currently Overvalued.
Does NetScientific PLC pay dividends?
NetScientific PLC does not currently pay dividends.
What is NetScientific PLC’s EPS estimate?
NetScientific PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NetScientific PLC have?
NetScientific PLC has 27,967,531 shares outstanding.
What happened to NetScientific PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NetScientific PLC?
Currently, no hedge funds are holding shares in DE:NTK1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NetScientific PLC
EMV Capital plc operates as a venture capital firm, primarily targeting investments across the full spectrum of early-stage funding, from seed rounds through to mid-stage and growth capital. Its investment mandate spans diverse high-growth sectors, including sustainability, life science, technology, transformative biomedical, deep tech, semiconductors, industrials, robotics, and artificial intelligence. The firm also places a strong emphasis on healthcare technologies, particularly digital health, diagnostics, and therapeutics, with a specific focus on ventures that enhance the lives and health outcomes of individuals battling chronic illnesses. Within digital health, core interests lie in data analytics, advanced wearable devices, and other related technologies. Geographically, EMV Capital seeks opportunities within developed European markets, including its home base in the United Kingdom, as well as the United States. While typical investment sizes reach up to £15 million (approximately $20.32 million), the firm retains the flexibility to commit larger sums. A strategic preference is to secure a controlling stake in key subsidiary companies, with investments primarily executed via its balance sheet. Established in 2008, EMV Capital plc operates from its headquarters in London, UK, with an additional presence in Beaconsfield.